These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 15784655)

  • 21. Magnolol suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting Ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways.
    Kim KM; Kim NS; Kim J; Park JS; Yi JM; Lee J; Bang OS
    Nutr Cancer; 2013; 65(8):1245-53. PubMed ID: 24066970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.
    Gao F; Vasquez SX; Su F; Roberts S; Shah N; Grijalva V; Imaizumi S; Chattopadhyay A; Ganapathy E; Meriwether D; Johnston B; Anantharamaiah GM; Navab M; Fogelman AM; Reddy ST; Farias-Eisner R
    Integr Biol (Camb); 2011 Apr; 3(4):479-89. PubMed ID: 21283904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells.
    Palanisamy K; Nareshkumar RN; Sivagurunathan S; Raman R; Sulochana KN; Chidambaram S
    Microvasc Res; 2019 Mar; 122():136-145. PubMed ID: 30144414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.
    Dhanabal M; Wu F; Alvarez E; McQueeney KD; Jeffers M; MacDougall J; Boldog FL; Hackett C; Shenoy S; Khramtsov N; Weiner J; Lichenstein HS; LaRochelle WJ
    Cancer Biol Ther; 2005 Jun; 4(6):659-68. PubMed ID: 15917651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
    Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
    J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
    Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
    Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
    Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells.
    Zhao Q; Du J; Gu H; Teng X; Zhang Q; Qin H; Liu N
    Pancreas; 2007 Mar; 34(2):242-7. PubMed ID: 17312464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
    Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
    Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells.
    Mu H; Ohashi R; Yan S; Chai H; Yang H; Lin P; Yao Q; Chen C
    Cardiovasc Res; 2006 Apr; 70(1):146-57. PubMed ID: 16515776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway.
    Nakashio A; Fujita N; Tsuruo T
    Int J Cancer; 2002 Mar; 98(1):36-41. PubMed ID: 11857382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
    Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J
    Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development.
    Carroll CE; Liang Y; Benakanakere I; Besch-Williford C; Hyder SM
    Int J Oncol; 2013 Jan; 42(1):179-87. PubMed ID: 23123638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compound K inhibits basic fibroblast growth factor-induced angiogenesis via regulation of p38 mitogen activated protein kinase and AKT in human umbilical vein endothelial cells.
    Jeong A; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Bae H; Kim SH
    Biol Pharm Bull; 2010; 33(6):945-50. PubMed ID: 20522957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
    Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
    Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.